MiNK Therapeutics (NASDAQ:INKT) president and CEO Dr Jennifer Buell speaks to Proactive about how the clinical-stage biopharmaceutical company is pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Buell explained that the company is currently advancing Phase 1 studies for solid tumour cancers and multiple myeloma, while a Phase 1/2 expansion is underway to evaluate agenT-797 in severe ARDS secondary to COVID-19 and influenza.